Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1865

Article

Fanaee-Danesh, Elham¹  Gali, Chaitanya Chakravarthi¹  Tadic, Jelena²  Zandl-Lang, Martina¹  Kober, Alexandra Carmen¹  Roca Agujetas, Vicente³  de Dios, Cristina^3,4  Tam-Amersdorfer, Carmen¹  Stracke, Anika¹  Albrecher, Nicole Maria¹  Manavalan, Anil Paul Chirackal¹  Reiter, Marielies¹  Sun, Yidan¹  Colell, Anna³  Madeo, Frank^2,5  Malle, Ernst⁶  Panzenboeck, Ute¹ 

[1] Med Univ Graz, Otto Loewi Res Ctr, Div Immunol & Pathophysiol, Heinrichstr 31a, A-8010 Graz, Austria

[2] Karl Franzens Univ Graz, Inst Mol Biosci, Graz, Austria

[3] CSIC, Dept Cell Death & Proliferat, Inst Invest Biomed Barcelona, IDIBAPS,Ctr Invest Biomed Red Enfermedades Neurod, Barcelona, Spain

[4] Univ Barcelona, Fac Med, Dept Biomed, Barcelona, Spain

[5] BioTechMed Graz, Graz, Austria

[6] Med Univ Graz, Gottfried Schatz Res Ctr, Div Mol Biol & Biochem, Graz, Austria

关键词: Blood-brain barrier;    Alzheimer's disease;    APP processing;    ABCA1;    Cholesterol efflux;    LRP-1;   

DOI  :  10.1016/j.bbadis.2019.04.019

来源: Elsevier

【 摘 要 】

The pathogenesis of Alzheimer's disease (AD) is characterized by overproduction, impaired clearance, and deposition of amyloid-beta peptides (A beta) and connected to cholesterol homeostasis. Since the blood-brain barrier (BBB) is involved in these processes, we investigated effects of the retinoid X receptor agonist, bexarotene (Bex), and the peroxisome proliferator-activated receptor a agonist and antioxidant, astaxanthin (Asx), on pathways of cellular cholesterol metabolism, amyloid precursor protein processing/A beta production and transfer at the BBB in vitro using primary porcine brain capillary endothelial cells (pBCEC), and in 3xTg AD mice. Asx/Bex down regulated transcription/activity of amyloidogenic BACE1 and reduced A beta oligomers and similar to 80 kDa intracellular 6E10-reactive APP/A beta species, while upregulating non-amyloidogenic ADAM10 and soluble (s)APP alpha production in pBCEC. Asx/Bex enhanced A beta clearance to the apical/plasma compartment of the in vitro BBB model. Asx/Bex increased expression levels of ABCA1, LRP1, and/or APOA-I. Asx/Bex promoted cholesterol efflux, partly via PPAR alpha/RXR activation, while cholesterol biosynthesis/esterification was suppressed. Silencing of LRP-1 or inhibition of ABCA1 by probucol reversed Asx/Bex-mediated effects on levels of APP/A beta species in pBCEC. Murine (m)BCEC isolated from 3xTg AD mice treated with Bex revealed elevated expression of APOE and ABCA1. Asx/Bex reduced BACE1 and increased LRP-1 expression in mBCEC from 3xTg AD mice when compared to vehicle-treated or non-Tg treated mice. In parallel, Asx/Bex reduced levels of A beta oligomers in mBCEC and A beta species in brain soluble and insoluble fractions of 3xTg AD mice. Our results suggest that both agonists exert beneficial effects at the BBB by balancing cholesterol homeostasis and enhancing clearance of A beta from cerebrovascular endothelial cells.

【 授权许可】

Free